Eyelids with yellow granulomas and cough – periocular xanthogranuloma associated with adult-onset asthma. A case study and an overview of clinical forms of juvenile xanthogranuloma and its therapy

Czech version

Authors: Z. Adam ¹; K. Veselý ²; I. Motyčková ³; P. Szturz ¹; R. Koukalová ⁴; Z. Řehák ⁴; A. Štouracová ⁵; J. Vaníček ⁶; M. Krejčí ¹; L. Pour ¹; L. Zahradová ¹; R. Hájek ¹; Z. Král ¹; J. Mayer ¹
Authors‘ workplace: Interní hematoonkologická klinika Lékařské fakulty MU a FN Brno, pracoviště Bohunice, přednosta prof. MUDr. Jiří Mayer, CSc. ¹; I. patologicko-anatomický ústav Lékařské fakulty MU a FN u sv. Anny Brno, přednostka prof. MUDr. Markéta Hermanová, Ph. D. ²; Oční klinika Lékařské fakulty MU a FN Brno, pracoviště Bohunice, přednostka prof. MUDr. Eva Vlková, CSc. ³; Oddělení nukleární medicíny, centrum PET Masarykova onkologického ústavu Brno, přednosta prim. MUDr. Karol Bolčák ⁴; Radiologická klinika Lékařské fakulty MU a FN Brno, pracoviště Bohunice, přednosta prof. MUDr. Vlastimil A. Válek, CSc. ⁵; Klinika zobrazovacích metod Lékařské fakulty MU a FN u sv. Anny Brno, přednosta MUDr. Jiří Vaníček, Ph. D. ⁶
Published in: Vnitř Lék 2012; 58(5): 365-377
Category: Case Reports

Overview

Histiocytic diseases caused by proliferation and accumulation of phagocytosing macrophages (foamy macrophages) have many clinical forms. These are classified under “juvenile xanthogranuloma” within the WHO classification of blood disorders. Localized forms with benign course include normolipaemic xanthomatosis, xanthogranuloma and necrobiotic xanthogranuloma. Disseminated forms in children take a form of so called “disseminated juvenile xanthogranuloma” or Erdheim-Chester disease in adults. We describe a case of a patient who, at 53 years of age, first noticed yellow granulomas on her eyelids. The disease progressed gradually and, at 59, affects the eyelids as well as their closest surroundings. According to MR and PET-CT, the disease gradually infiltrated the inside of the orbit, orbital fat as well as extraocular muscles and started to cause exoftalmus of one of the eyes. Propagation of the xanthogranuloma into the orbit and infiltration of extraocular muscles might impair eye function. Over the last year, the patient complained of cough. Pulmonary function evaluation confirmed recent asthma bronchiale. These findings correspond to periocular xanthogranuloma associated with adult-onset asthma. No other abnormities have been shown in this patient. Exoftalmus was observed in 2011 after 6 years of monitoring with very slow progression of eyelid and extraocular infiltration. Therefore, prednisone was initiated in 2011, leading to cessation of exoftalmus. It is not known at present whether this is a permanent improvement with a suppression of histiocytary proliferation or whether this was a temporary improvement due to suppression of inflammatory changes in the xanthogranuloma with no effect on histiocytary proliferation. Progression during therapy with corticosteroids would warrant cytostatic treatment. The discussion section provides an overview of diseases caused by foamy histiocytes with illustrations and an overview of experiences with their treatment.

Key words:
foamy histiocytes – juvenile xathogranuloma – normolipemic xanthoma planum – adult onset periocular xanthoranuloma – adult onset asthma and periocular xanthogranuloma – necrobiotic xanthogranuloma – Erdheim-Chester disease – monoclonal gammopathy – 2-chlorodeoxyadenosin – cladribin – thalidomid – lenalidomid

Sources

1. Plank L. Diagnostická patológia non-Langerhans cell histiocytóz. Vnitř Lék 2010; 56: (Suppl 2): 2S39–2S63.

2. Guo J, Wang J. Adult ortbital xantogranulomatous disease: review of the literature. Arch Pathol Lab Med 2009; 133: 1994–1997.

3. Sivak-Callcott JA, Tootman J, Rasmussen SL et al. Adult xantogranulomatous diseaase of the orbit and ocular adnexa: new imunohistochemical findings and clinical review. Brit J Ophthalmol 2006; 90: 602–608.

4. Vick VL, Wilson MV, Fleming JC et al. Orbital and eyelid manifestation of xanthogranulomatous disease. Orbit 2006; 25: 221–225.

5. Janssen D, Fölster-Holst R, Harms D et al. Clonality in juvenile xanthogranuloma. Am J Surg Pathol 2007; 31: 812–813.

6. Decaux O, Laurat E, Perlat A et al. Systemic manifestations of monoclonal gammopathy. Eur J Intern Med 2009; 20: 457–461.

7. Alexander AS, Turner R, Uniate L et al. Xanthoma diseminatum, a case report and literature review. Br J Radiology 2005; 78: 153–157.

8. Vick VL, Wilson MW, Fleming JC et al. Orbital and eyelid manifestations of xanthogranulomatous diseases. Orbit 2006; 25: 221–225.

9. Asarch A, Thiele JJ, Ashby-Richardson H et al. Cutaneous disseminated xantogranulomu in adult. A case report and review of the literature. Cuits 2009; 83: 243–249.

10. Altman J, Winkelmann RK. Difuse normolipemic planae xanthoma: Generalized xanthelasma. Arch Dermatol 1962; 85: 633–640.

11. Mencía-Gutiérrez E, Gutiérrez-Diaz E, Madero-García S. Juvenile xanthogranuloma of the orbit in an adult. Ophthalmologica 2000; 214: 437–440.

12. Rouhiainen H, Nerdrum K, Puustjärvi T et al. Xanthogranuloma juvenile – a rare cause of orbital swelling in adulthood. Ophthalmologica 1992; 204: 162–165.

13. Cavallazzi R, Hirani A, Vasu TS et al. Clinical manifestations and treatment of adult-onset asthma and periocular xanthogranuloma. Can Respir J 2009; 16: 159–162.

14. Jakobiec FA, Mills MD, Hidayat AA et al. Periocular xanthogranulomas associated with severe adult-onset asthma. Trans Am Ophthalmol Soc 1993; 91: 99–129.

15. Hammond MD, Niemi EW, Ward TP et al. Adult orbital xanthogranuloma with associated adult-onset asthma. Ophthal Plast Reconstr Surg 2004; 20: 329–332.

16. Jakobiec FA, Mills MD, Hidayat AA et al. Periocular xantogranulomas associated with severe adult-onset asthma. Trans Am Ophthalmol Soc 1993; 91: 99–125.

17. Sivak-Callcott JA, Lim WK, Seah LL et al. Xantogranulomatous disease in the lacrimal gland. Br J Ophthalmol 2005; 89: 1375–1377.

18. Wood AJ, Wagner MV, Abbott JJ et al. Necrobiotic xanthogranuloma: a review of 17 cases with emphasis on clinical and pathologic correlation. Arch Dermatol 2009; 145: 279–284.

19. Kossard S, Winkelmann RK. Netrobiotic xanthogranuloma with paraproteinemia. J Amer Acad Dermatol 1980; 3: 257–270.

20. Rayner SA, Duncombe AS, Keefe M et al. Necrobiotic xanthogranuloma occurring in an eyelid scar. Orbit 2008; 27: 191–194.

21. Karcioglu ZA, Sharara N, Boles TL et al. Orbital xanthogranuloma: clinical and morphologic features in eight patients. Ophthal Plast Reconstr Surg 2003; 19: 372–381.

22. Cornblath WT, Dotan SA, Trobe JD et al. Varied clinical spectrum of necrobiotic xanthogranuloma. Ophthalmology 1992; 99: 103–107.

23. Ugurlu S, Bartley GB, Gibbon LE. Necrobiotic xanthogranbuloma, long-term outcome of ocular and systemic involvement. Am J Ophthalmol 2000; 129: 651–657.

24. Mehregan DA, Winkelmann RK. Necrobiotic xanthogranuloma. Arch Dermatol 1992; 128: 94–100.

25. Finan MC, Winkelmann RK. Necrobiotic xanthogranuloma with paraproteinemia. A review of 22 cases. Medicine (Baltimore) 1986; 65: 376–388.

26. Martínez Fernández M, Rodríguez Prieto MA, Ruiz Gonzalez I. Necrobiotic xanthogranloma associated with myeloma. J Eur Acad Dermatol Venereol 2004; 18: 328–331.

27. Oumeish OY, Oumeish I, Tarawneh M et al. Necrobiotic xanthogranuloma associated with paraproteinemia and non-Hodgkin’s lymphoma developing into chronic lymphocytic leukemia: the first case reported in the literature and review of the literature. Int J Dermatol 2006; 45: 306–310.

28. Winkelmann RK, Dahl PR, Perniciaro C. Asteroid bodies and other cytoplasmic inclusions in necrobiotic xanthogranuloma with paraproteinemia. J Am Acad Dermatol 1998; 38: 967–970.

29. Randell PL, Heenan PJ. Necrobiotic xanthogranuloma with paraproteinaemia. Australas J Dermatol 1999; 40: 114–115.

30. Robertson DM, Winkelmann RK. Ophthalmic features of necrobiotic xanthogranuloma with paraproteinemia. Am J Ophthalmol 1984; 97: 173–183.

31. Martínez Fernandez M, Rodríguez Prieto MA, Ruíz Gonzáles I et al. Necrobiotic xanhtogranuloma associated with myeloma. J Eur Acad Dermatol Venereol 2004; 18: 328–331.

32. Lynch PJ, Winkelmann RK. Generalised plane xanthoma and systemic disease. Arch Dermatol 1966; 93: 639–640.

33. Williford PM, White WL, Jurizzo JL et al. The spektrum of normolipemic plane xanthomas. Amer J Dermatopahol 1993; 15: 572–575.

34. Taylor JS, Lewis LA, Battle JD et al. Plane xanthoma and multiple myeloma with lipoprotein-paraprotein complexing. Arch Dermatol 1978; 114: 425–431.

35. Marcoval J, Moreno A, Bordas X et al. Diffuse plane xanthoma: clinicopathologic study of 8 cases. J Am Acad Dermatol 1998; 39: 439–442.

36. Adam Z, Zahradová L, Krejčí M et al. Difuzní plošná normolipemická xantomatóza a nekrobiotický xantogranulom, asociované s monoklonální gamapatií – přínos PET-CT pro stanovení rozsahu nemoci a zkušenosti s léčbou. Popis dvou případ a přehled literatury. Vnitř Lék 2010; 56: 1159–1168.

37. Boström J, Janssen G, Messing-Jünger M et al. Multiple intracranial juvenilie xanthogranulomas. Case report. J Neurosurg 2000; 93: 335–341.

38. Fernández-Herrera J, Pedraz J. Necrobiotic xanthogranuloma. Semin Cutan Med Surg 2007; 26: 108–113.

39. Machado S, Alves R, Lima M et al. Cutaneous necrobiotic xanthogranuloma (NXG): succesfully treated with low dose chlorambucil. Eur J Dermatol 2001; 11: 458–462.

40. Hunter L, Burry AF. Necrobiotic xantothogranuloma. A systemic disease with paraproteinemia. Patology 1985; 17: 533–536.

41. Fortson JS, Schroeter AL. Necrobiotic xanthogranuloma with IgA paraproteinemia and extracutaneous involvement. Amer J Dermatopathol 1990; 12: 579–584.

42. Bara C, Barbarot S, Hamitou M et al. Systemic necrobiotic xanthogranuloma with initial pericaridal and pulmonary involvement. Ann Dermatol Venereol 2003; 130: 341–344.

43. Novak PM, Robins TO, Winkelmann RK. Necrobiotic xanthogranuloma with myocardial lesions and nodular transformation of the liver. Hum Pathol 1992; 23: 195–196.

44. Shah KC, Poonnoose SI, Georgie R et al. Necrobiotix xanthogranuloma with cutaneous and cerebral manifestaion. Case report and review of the literature. J Neurosurg 2004; 100: 1111–1114.

45. Umbert I, Winkelmann RK. Necrobiotic xanthogranuloma with cardiac involvement. Br J Dermatol 1995; 133: 438–443.

46. Yasukawa K, Kato N, Hamasaka A et al. Necrobiotic xanthogranuloma: isolated skleletal and muscle involvement and unusual changes J Am Acad Dermatol 2005; 52: 729–731.

47. Winkelmann RK, Litzow, MR, Umbert IJ et al. Giant cell granulomatous pulmonary and myocardial lesions in necrobiotic xanthogranuloma with paraproteinemia. Mayo Clin Proc 1997; 72: 1028–1033.

48. Bakir B, Unuvar E, Terzibasioglu E et al. Atypical lung involvement in a patient with systemic juvenile xanthogranuloma. Pediatr Radiol 2007; 37: 325–327.

49. Amer R, Peer J, Pappo O et al. Necrobiotic xanthogranuloma associated with chorioidal infiltration and syncytial gian cell hepatitis. J Neuroophthalmol 2005; 25: 189–192.

50. Betts CM, Pasguinelli G, Costa AM et al. Necrobiotic xanthogranuloma without periorbital involvement: an ultrastructural investigation. Ultrastruct Pathol 2001; 25: 437–444.

51. Orsey A, Paessler M, Lange BJ et al. Central nervous system juvenile xanthogranuloma with malignant transformation. Pediatr Blood Cancer 2008; 50: 927–930.

52. Ozçelik U, Doğru D, Akçören Z et al. Xanthoma disseminatum a child with respiratory system involvement and bronchiectasias. Pediatr Pulmonol 2005; 39: 84–87.

53. Smith HC, Sargent LD, Lundin DB. Necrobiotic xanthogranuloma of the chest wall. Dermatol Online 2006; 12: 12–16.

54. Stockman A, Delanghe J, Geerts ML et al. Diffuse plane normolipaemic xanthomatosis in a patient with chronic lymphatic leukaemia and monoclonal gammopathy. Dermatology 2002; 204: 351–354.

55. Stork J, Kodetová D, Vosmík E et al. Necrobiotic xanthogranuloma presenting as a solitary tumor. Am J Dermatopathol 2000; 22: 453–456.

56. Spicknall KE, Mehregan DA. Necrobiotic xanthogranuloma. A rewiev. Int J Dermatol 2009; 48: 1–10.

57. Tucker NA, Discepola MJ, Blanco G et al. Necrobiotic xanthogranuloma without dermatologic involvement. Can J Ophthalmol 1997; 32: 396–399.

58. Ferrara G, Palombi N, Lipizzi A et al. Nonnecrobiotic necrobiotic xanthogranuloma. Am J Dermatopathol 2007; 29: 306–308.

59. Bullock JD, Bartley GB, Campbell RJ et al. Necrobiotic xantogranuloma with paraproteinemia. Case report and pathogenetic study. Trans Am Ophthalmol Soc 1986; 84: 342–354.

60. Yağci B, Varan A, Altmock G et al. Xanthoma disseminatum in a child with cranial involvement. J Pediatr Hematol Oncol 2008; 30: 310–312.

61. Weitzman S, Jaffe R. Uncommon histiocytic disorders: the non-Langerhans cell histiocytoses. Pediatr Blood Cancer 2005; 45: 256–264.

62. Moore FO, Berne JD, Fox AD. Mesenteric panniculitis and Erdheim-Chester disease: xanthogranulomatous diseases confused with malignancy. J Am Coll Surg 2007; 204: 326–327.

63. Nestle FO, Hofbauer G, Burg G. Necrobiotic xanthogranuloma with monoclonal gammopathy of the IgG λ type. Dermatology 1999; 198: 434–435.

64. Hafner O, Witte T, Schmidt RE et al. Necrobiotic xanthogranuloma in IgG κ plasmacytoma and Quincke edema. Hautarzt 1994; 45: 339–343.

65. Matsuura F, Yamashita S, Hirano K et al. Activation of monocytes in vivo couses intracellular accumulation of lipoprotein derived lipids and marked hypocholesterolemia. A possible pathogenesis of necrobiotic xanthogranuloma. Atheroslerosis 1999; 142: 355–365.

66. Jeziorska M, Hassan A, Mackness MI et al. Clinical, biochemical, and immunohistochemical features of necrobiotic xanthogranulomatosis. J Clin Pathol 2003; 56: 64–68.

67. Langlois S, Brochot P, Reguiai Z et al. Necrobiotic xanthogranuloma with multiple myeloma. Case report and pathogenic hypotheses. Joint Bone Spine 2006; 73: 120–122.

68. Zelger B, Eisendle K, Mensing C et al. Detection of spirochetal microorganism by focus bloating microscopy in necrobiotic xanthogranuloma. J Amer Acad Dermatol 2007; 57: 1026–1030.

69. Chang SE, Lee WS, Lee MW et al. A case of necrobiotic xanthogranuloma without paraproteinemia presenting as a solitary tumor on the thigh. Int J Dermatol 2003; 42: 470–472.

70. Jung WS, Ahn KJ, Park MR et al. The radiological spectrum of orbital pathologies that involve the lacrimal gland and the lacrimal fossa. Korean J Radiol 2007; 8: 336–342.

71. Miszkiel KA, Sohaib SA, Rose GE et al. Radiological and clinicopathological features of orbital xanthogranuloma. Br J Ophthalmol 2000; 84: 251–258.

72. Malhotra R, Porter RG, Selva D. Adult orbital xanthogranuloma with periosteal infiltration. Br J Ophthalmol 2003; 87: 120–121.

73. Hidayat AA, Mafee MF, Laver NV et al. Langerhans’ cell histiocytosis and juvenile xanthogranuloma of the orbit. Clinicopathologic, CT, and MR imaging features. Radiol Clin North Am 1998; 36: 1229–1240.

74. Tang WK, Lee KC, Chong LY. Three patients with orbital xanthogranuloma and non-progressive haematological abnormalities. Australas J Dermatol 2003; 44: 185–189.

75. Wee SA, Shupack JL. Necrobiotic xanthogranuloma. Dermatol Online J 2005; 11: 24–25.

76. Cornblath WT, Dotan SA, Trobe JD et al. Varied clinical spectrum of necrobiotic xanthogranuloma. Ophthalmology 1992; 99: 103–107.

77. Elner VM, Mintz R, Demirci H et al. Local corticosteroid treatment of eyelid and orbital xanthogranuloma. Trans Am Ophthalmol Soc 2005; 103: 69–73.

78. Sabet LM, Wexler D, Salama S et al. An unuusual cause of refractive chronic bilateral leg ulceration. J Cutan Med Surg 2004; 8: 432–437.

79. Chave TA, Chowdhury MM, Holt PJ. Recalcintrant necrobiotic xantohogranuloma responding do pulsed high dose dexametasone plus maintenance therapy with oral prednisolone. Br J Dermatol 2001; 144: 158–161.

80. Valentine EA, Friedman HD, Zamkoff KW et al. Necrobiotic xanthogranuloma with IgA multiple myeloma: a case report and literature review. Am J Hematol 1990; 35: 283–285.

81. Venencie PY, Le Bras P, Toan ND et al. Recombinant interferon α-2b treatment of necrobiotic xanthogranuloma with paraproteinemia. J Am Acad Dermatol 1995; 32: 666–667.

82. Scupham RK, Fretzin DF. Necrobiotic xanthogranuloma with paraproteinemia. Arch Pathol Lab Med 1989; 113: 1389–1391.

83. Plotnick H, Taniguchi Y, Hashimoto K et al. Periorbital necrobiotic xanthogranuloma and stage I multiple myeloma. Ultrastructure and response to pulsed dexamethasone documented by magnetic resonance imaging. J Am Acad Dermatol 1991; 25: 373–377.

84. Kossard S, Chow E, Wilkinson B et al. Lipid and giant cell in nercobiotic xanthogranuloma. J Cutan Pathol 2000; 27: 374–378.

85. Wells J, Gillespie R, Zardawi I. A case ofr recaltitrant necrobiotic xanthogranuloma. Australas J Dermarol 2004; 45: 213–215.

86. Meyer S, Szeimies RM, Landthaler M et al. Cyclophosphamide-dexamethasone pulsed therapy for treatment of recalcitrant necrobiotic xanthogranuloma with paraproteinemia and ocular involvement. Br J Dermatol 2005; 153: 443–445.

87. Stover DG, Alapati S, Regueira O et al. Treatment of juvenile xanthogranuloma. Pediatr Blood Cancer 2008; 51: 130–133.

88. Seaton ED, Pillai GJ, Chu AC. Treatment of xanthoma diseminatum with cylophosphamide. Br J Dermatol 2004; 150: 346–349.

89. Flann S, Wain EM, Halpern S et al. Necrobiotic xanthogranuloma with paraproteinaemia. Clin Exp Dermatol 2006; 31: 248–251.

90. Chave TA, Hutchinson PE. Necrobiotic xanthogranuloma with two monoclonal paraproteins and no periorbital involvement at presentation. Clin Exp Dermatol 2001; 26: 493–466.

91. Khan IJ, Azam NA, Sullivan SC et al. Necrobiotic xanthogranuloma successfully treated with combination of dexamethasone and oral cyclophosphamide. Can J Ophthalmol 2009; 44: 335–336.

92. Hauser C, Schifferli J, Saurath JH. Complement consumption in a patient with necorbiotic xanthogranuloma and paraproteinemia. J Am Acad Dermatol 1991; 24: 908–911.

93. Torabian SM, Fazel N, Knuttle R. Necrobiotic xanthogranuloma treated with chlorambucil. Dermatol Online J 2006; 12: 11–12.

94. Luck J, Layton A, Noble BA. Necrobiotix xanthogranuloma with orbital involvement. J R Soc Med 1992; 85: 357–358.

95. Criado PR, Vasconcellos C, Pegas JR et al. Necrobiotic xanthogranuloma with λ paraproteinemia: case report of successful treatment with melphalan and prednisone. J Dermatolog Treat 2002; 13: 87–89.

96. Ito Y, Nishimura K, Yamanaka K et al. Necrobiotic xanthogranuloma with paraproteinemia; an atypical case. J Dtsch Dermatol Ges 2008; 6: 40–43.

97. Russo CG. Necrobiotic xanthogranuloma with scleroderma. Cutis 2002; 70: 311–316.

98. Saeki H, Tomita M, Kai H et al. Necrobiotic xanthogranuloma with paraproteinemia successfully treated with melphalan, prednisolone and skin graft. J Dermatol 2007; 34: 795–797.

99. Wilhelmus KR, Yen MT, Rice L et al. Necrobiotic xanthogranuloma with posterior scleritis. Arch Ophthalmol 2006; 124: 748–749.

100. Ziemer M, Wedding U, Sander CS et al. Necrobiotic xanthogranuloma-rapid progression under treatment with melphalan. Eur J Dermatol 2005; 15: 363–365.

101. Rose GE, Patel BC, Gerner A et al. Orbita xanthogranuloma in adults. Br J Ophthalmol 1991; 75: 680–684.

102. Hayden A, Wilson DJ, Rosenbaum JT. Management of orbital xanthogranuloma with methotrexate. Br J Ophthalmol 2007; 91: 434–436.

103. Georgiou S, Monastirli A, Kapramos N et al. Interferon α-2a monothherapy for necrobiotic xanthogranuloma. Acta Derm Venereol 1999; 79: 484–485.

104. Finelli LG, Ratz JL. Plasmapheresis, a treatment modality for necrobiotic xanthogranuloma. J Am Acad Dermatol 1987; 17: 351–354.

105. Lorenz S, Hohenleutner S, Hohenleutner U et al. Treatment of difuse plane xantohomas of the face with the erbium: YAG Laser. Arch Dermatol 1978; 114: 425–431.

106. Vieira V, Del Pozo J, Martínez W et al. Necrobiotic xanthogranuloma associated with lymphoplasmacytic lymphoma. Palliative treatment with carbon dioxide laser. Eur J Dermatol 2005; 15: 182–185.

107. Efebera Y, Blanchard E, Allam C et al. Complete response to thalidomide and dexamethasone in a patient with necrobiotic xanthogranuloma associated with monoclonal gammopathy: a case report and review of the literature. Clin Lymphoma Myeloma Leuk 2011; 11: 298–302.

108. Silapunt S, Chon SY. Generalized necrobiotic xanthogranuloma successfully treated with lenalidomide. J Drugs Dermatol 2010; 9: 273–276.

109. Sheidow TG, Nicolle DA, Heathcote JG. Erdheim-Chester disease: two cases of orbital involvement. Eye (Lond) 2000; 14: 606–612.

110. Myra C, Sloper L, Tighe PJ et al. Treatment of Erdheim-Chester disease with cladribine: a rational approach. Br J Ophthalmol 2004; 88: 844–847.

111. Aouba A, Larousserie F, Le Guern V et al. Spumous histiocytic oligoarthritis coexisting with systemic Langerhans’ cell histiocytosis: case report and literature review. Joint Bone Spine 2009; 76: 701–704.

112. Blouin P, Yvert M, Arbion F et al. Juvenile xanthogranuloma with hematological dysfunction treated with 2CDA-AraC. Pediatr Blood Cancer 2010; 55: 757–760.

113. Khezri F, Gibson LE, Tefferi A. Xanthoma disseminatum: effective therapy with 2-chlorodeoxyadenosine in a case series. Arch Dermatol 2011; 147: 459–464.

114. Rajendra B, Duncan A, Parslew R et al. Successful treatment of central nervous system juvenile xanthogranulomatosis with cladribine. Pediatr Blood Cancer 2009; 52: 413–415.

115. Orsey A, Paessler M, Lange BJ et al. Central nervous system juvenile xanthogranuloma with malignant transformation. Pediatr Blood Cancer 2008; 50: 927–930.

116. Adam Z, Koukalová R, Šprláková A et al. Úspěšná léčba Erdheimovy-Chesterovy nemoci chemoterapií obsahující 2-chlorodeoxyadenosine. Popis dvou případů a přehled literatury. Vnitř Lék 2011; 57: 576–589.

117. Khezri F, Gibson LE, Tefferi A. Xanthoma disseminatum: effective therapy with 2-chlorodeoxyadenosine in a case series. Arch Dermatol 2011; 147: 459–464.

118. Goede JS, Misselwitz B, Taverna C et al. Necrobiotic xanthogranuloma successfully treated with autologous stem cell transplantation. Ann Hematol 2007; 86: 303–306.

119. Hallermann C, Tittelbach J, Norgauer J et al. Succesfull treatment of necrobiotic xanthogranuloma with intravenous immunoglobulin. Arch Dermatol 2010; 146: 957–960.